REG - IXICO plc - Contract Win

IXICOAnnouncement

18/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230718:nRSR2350Ga&default-theme=true

RNS Number : 2350G  IXICO plc  18 July 2023

18 July 2023

IXICO plc

 

("IXICO", the "Company" or the "Group")

 

Contract win for a Phase 3 Progressive Supranuclear Palsy (PSP) study;

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, announces that it has signed
a contract with a new client. IXICO will provide its imaging services in
a clinical trial of a novel therapeutic to treat Progressive Supranuclear
Palsy, a rare neurodegenerative disease. The contract value is circa US$1.7m
(circa £1.3m), over a 4-year term. The World Health Organization defines a
rare disease as one that strikes fewer than 65 per 100,000
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345065/)  people.

 

 Giulio Cerroni, CEO of IXICO, commented: "Rare diseases are a global health
priority with about 95% of all rare diseases not yet having treatments. This
new contract exemplifies the traction we are building beyond our strong market
position in HD into other rare neuro disorders to expand our market
opportunities and acquire new clients in the dynamic field of rare
neurological diseases(1)."

 

(1)National Organisation of Rare Diseases

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499

 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900

 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUBOKRONUBARR